Navigation Links
Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
Date:11/4/2008

- Company Also Announces Participation in Upcoming Investor Conferences in

November -

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for November 2008, which includes the teleconference and webcast of its third quarter 2008 financial results as well as upcoming corporate presentations at noteworthy investor conferences.

On November 6, 2008 at 5:00 p.m. Eastern time, Orexigen management will host the call and webcast to discuss the financial results for the third quarter ended September 30, 2008, and recent business highlights. The live call may be accessed by calling 800-860-2442 (domestic) or 412-858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's web site at http://www.orexigen.com and will be archived for 14 days following the call.

Upcoming Corporate Presentations

Rodman & Renshaw 10th Annual Healthcare Conference

New York Palace Hotel, New York

November 11, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

St. Regis Hotel, New York

November 18, 2008

11:25 a.m. EST

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Arno Therapeutics Appoints William F. Hamilton to Board of Directors
4. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
5. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
6. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
7. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
8. Synvista Therapeutics Appoints William Federici to its Board of Directors
9. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
10. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: